New hope for Tough-to-Treat ovarian cancer
NCT ID NCT06028932
Summary
This study is testing a drug called sacituzumab govitecan in people with ovarian, fallopian tube, or primary peritoneal cancer that has returned and is resistant to standard platinum-based chemotherapy. The goal is to see if this targeted drug can shrink tumors and control the disease. The study is for up to 20 participants who meet specific health criteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.